Cognitive Systems Launches Caregiver Aware, Enabling Service Providers to Enter the Remote Eldercare Industry
4.5.2022 14:50:00 EEST | Business Wire | Press release
Cognitive Systems Corp. announced today the launch of Caregiver Aware, a revolutionary advancement in preventative health. Working directly with service providers during development to understand their challenges, Caregiver Aware was designed with flexible go-to-market options that leverage providers’ existing infrastructure and hardware. Building on the success of its Home Aware security product that commercially launched in 2019, Caregiver Aware’s predictive analytics has the potential to significantly disrupt the broadband services market and our definition of “smart home.”
Caregiver Aware is powered by WiFi Motion™, which is currently active in over 70 countries and leverages connected IoT devices to transform the entire home into a motion-sensing network without additional hardware. It is an end-to-end solution featuring Cognitive Systems' patented algorithms, clean iOS and Android app interfaces. Backed by robust integration support from Cognitive’s QA and commercialization experts, the optimized data management system does not impact broadband performance. This launch represents a key moment for service providers looking to enter the rapidly growing field of remote eldercare by providing their customers with a tool for aging in place.
“Technology is accelerating the shift from reactive to proactive healthcare and we want to help lead that charge,” said Taj Manku, co-founder and CEO of Cognitive Systems. “Caregiver Aware has been on our product roadmap from the start, but the pandemic has made us all acutely aware of the need for innovation in preventative health. Our goal with this product is to create a bridge for service providers to build a care-focused ecosystem using data analytics, which will be a game-changing step in shaping future broadband services.”
Caregiver Aware is currently being trialed with service provider partners. It allows caregivers to complete remote wellness checks and view live motion in a loved one's home without intruding on their privacy or independence in the way cameras or wearable devices do. This launch represents the tip of the iceberg for remote eldercare monitoring, with new features already in development aimed at capturing behavioural patterns based on natural motion AI, improving localization and enabling customized notifications.
“As we worked towards a full-scale launch with more advanced features, user feedback confirmed immediate value in providing people with the peace of mind knowing a loved one is home, safe and active,” says Amanda Forsyth, Director of Product Management at Cognitive Systems. “This first iteration of Caregiver Aware is an important steppingstone towards a proactive health model and, with the majority of adults wanting to age in place, Caregiver Aware not only fills an industry need but a societal one.”
With aging populations around the world, the remote eldercare industry is poised to take off. However, with current world events and chip shortages, integration timelines can be lengthy. Service providers looking to enter the market need to start conversations now about where care solutions fit into their product roadmaps.
Learn more about how WiFi Sensing is ushering in a new era of preventative healthcare here.
About Cognitive Systems
Cognitive Systems Corp. is on a mission to transform the way WiFi networks are used. Its flagship technology, WiFi Motion™, uses wireless signals to sense motion in the home. WiFi Motion harnesses artificial intelligence and predictive analytics to reliably identify and localize motion for the smart home, home monitoring, and wellness monitoring markets. This patented technology is layered onto existing WiFi networks without additional hardware to enhance service provider and router manufacturer offerings.
www.cognitivesystems.com
https://www.linkedin.com/company/cognitive-systems-corp-/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005187/en/
Contact information
Press
Proof Strategies
Jillian Colucci
jcolucci@getproof.com
416-801-9851
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom